SCHEMBL2761656

SCHEMBL2761656

CC1(C)OC(=O)c2c(OC3CCCCC3)cccc2O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 1/20 0.40
▸ HPGD P15428 1/20 0.38
▸ MCHR1 Q99705 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ CARM1 Q86X55 2/20 0.34
▸ PRMT1 Q99873 2/20 0.34
▸ ITGB1 P05556 1/20 0.33
▸ ITGA4 P13612 1/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ PDE4A P27815 3/20 0.33
▸ PDE4B Q07343 3/20 0.33
▸ PDE4C Q08493 3/20 0.33
▸ PDE4D Q08499 3/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27379609 0.86 ALDH1A1 (0.34) PTGS2ALDH1A1HTR2CCARM1PRMT1
SCHEMBL620108 0.83 KAT2B (0.37) ALDH1A1HTR2CPDE4APDE4BPDE4C
SCHEMBL620109 0.83 KAT2B (0.37) ALDH1A1HTR2CPDE4APDE4BPDE4C
SCHEMBL26604850 0.80 CA12 (0.41) PTGS2ALDH1A1PDE4APDE4BPDE4C
SCHEMBL12676736 0.79 IDO1 (0.43) HPGDMCHR1
SCHEMBL23655043 0.76 ALDH1A1 (0.48) HPGDALDH1A1HTR2CTDP1MAPK1
SCHEMBL2761782 0.76 HPGD (0.42) HPGDMCHR1
SCHEMBL27032900 0.74 ALDH1A1 (0.40) ALDH1A1HTR2CTDP1MAPK1HSD17B10
SCHEMBL21957987 0.73 CHRNB4 (0.48) —
Hydrochloric Acid SCHEMBL21957985 0.73 CHRNB4 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 — — US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 — — US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 PTGS2 171/4885HPGD 37/4885MCHR1 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback